Online inquiry

IVTScrip™ mRNA-Anti-IL12B, CNTO 1275(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6023MR)

This product GTTS-WQ6023MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets IL12B gene. The antibody can be applied in Psoriatic arthritis (PSA) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_002187.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3593
UniProt ID P29460
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL12B, CNTO 1275(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ6023MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6470MR IVTScrip™ mRNA-Anti-S, CT-P-59(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CT-P-59
GTTS-WQ2130MR IVTScrip™ mRNA-Anti-CGRP, ALD-403(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ALD-403
GTTS-WQ6199MR IVTScrip™ mRNA-Anti-CD40, CP-870893(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CP-870893
GTTS-WQ8045MR IVTScrip™ mRNA-Anti-F, H1H3592P3(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA H1H3592P3
GTTS-WQ9376MR IVTScrip™ mRNA-Anti-IL2R, Interleukin 2(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA Interleukin 2
GTTS-WQ431MR IVTScrip™ mRNA-Anti-AMHR2, 3C23K(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA 3C23K
GTTS-WQ10368MR IVTScrip™ mRNA-Anti-APP, LY2062430(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA LY2062430
GTTS-WQ956MR IVTScrip™ mRNA-Anti-CD40, ABBV-323(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABBV-323
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW